An AI-native pharmaceutical company launched with approximately $1 billion, integrating Protein Design and the Virtual Cell 'X-Cell'The reason for featuring Xaira Therapeutics in this 20-company ...
Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027 Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results